Vol. 6 (02) pp. 1792-1801 DOI: 10.21474/IJAR01/6619

SERUM FETUIN- A LEVEL AND RENAL IMPAIRMENT INDUCED BY OBESITY IN COMPARISON WITH RENAL IMPAIRMENT INDUCED BY GENTAMICIN IN RATS.

, , and
  • Physiology Department, Faculty of Medicine, Tanta University, Egypt.
19 Downloads 121 Views
Crossref

Download Full Paper (PDF)

Abstract

Aim of the work: is to investigate the relation between serum fetuin-A level and renal impairment induced by obesity in comparison with that induced by gentamicin in rats and to determine the effect of fenofibrate treatment. Materials and Methods: 58 male rats were divided into four groups Control group: 15 rats were fed standard chow diet. Obese group 13 rats were fed a High fat diet (HFD). Then, albumin/ creatinine ratio (ACR) was done and according to the result of this test, this group was diagnosed as obese group with renal impairment. Fenofibrate treated obese group: 15 rats were fed a HFD along with fenofibrate. Gentamicin induced renal impairment group: 15 rats were fed stander chow diet. In the last eight days they were injected intraperitoneally with gentamicin. Body mass index (BMI) was measured. Urine was collected albumin, creatinine were measured in urine, blood was collected and serum urea, creatinine, fetuin-A, adiponectin, tumor necrosis alpha (TNF-?), malondialdehyde (MDA), reduced glutathione, fasting glucose, insulin, HOMA IR, lipid profile, calcium, phosphorus and solubility product were measured. Results: Fetuin ?A was significantly increased in obese group with renal impairment. This group also showed significant increase in ACR, serum urea, creatinine and phosphorus. Also, there was positive correlation between serum fetuin-A and BMI, ACR with a negative correlation between it and adiponectin. Also, it showed significant decrease in adiponectin, reduced glutathione and HDL and significant increase in BMI, TNF-?, MDA, Insulin, HOMA IR, triglyceride, LDL. However, fenofiberates intervention was associated with significant correction of all these parameters. In gentamicin induced renal impairment group, there was only significant increase in ACR, serum urea, creatinine, TNF-?, MDA and significant decrease in reduced glutathione. Fetuin-A shows no significant change when compared to control group. Conclusion: Fetuin-A may be associated with obesity-related renal impairment. So, more researches should done to investigate whether reduction of serum fetuin-A may hamper the development and progression of obesity-related complications or not. Also fenofibrate is found to be protective to renal impairment with obesity.

Keywords

Article Analytics

References

1. Assmann G., Jabs HU., Kohnert U., Nolte W. and Schriewer H. (1984): LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate. Clinica Chimica Acta, 140(1):77-83. 2. Bartles H., Bohmer M. and Heirli C. (1972): Serum creatinine determination without protein precipitation. Clin Chem Acta; 37: 193-197. 3. Baure JD. (1982): Clinical Laboratory Methods (1982). Cv Mosby, USA. 9th ed. 1121: 495-496. 4. Beutler E., Duron O. and Kelly MB. (1963): Improved method for the determination of blood glutathione. J. Lab. Clin. Med.; 61:882-888. 5. Bijland S., Pieterman EJ, Maas AC, van der Hoorn JW, van Erk MJ, van Klinken JB, Havekes LM, van Dijk KW, Princen HM. and Rensen PC. (2010): Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice J Biol Chem. ;285(33): 68-75 6. Brouckaert P., Libert C., Takahashi N., Cauwels A. and Fiers W. (1993): Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology; 187: 317-329. 7. Han C.Y., (2016): Roles of reactive oxygen species on insulin resistance in adipose tissue. Diabetes & Metabolism Journal; 40(4): 272-279. 8. Chen HY., Chiu YL., Hsu SP., Pai MF., Lai CF., Peng YS., Kao TW., Hung KY., Tsai TJ. and Wu KD.(2009: Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. Eur J Endocrinol; 160(5):777-783. 9. Chevenne D., Ruiz J., Lohmann L., Laudat A., Leblanc H., Gray IP., Passa P. and Porquet D. (1994): Immunoradiometric assay of human intact pro-insulin applied to patients with type 2 diabetes, impaired glucose tolerance, and hyperandrogenism. Clin Chem.; 40:754-7. 10. Daly JA. and Ertingshausen G. (1972): Direct method for inorganic phosphate determination. Clin Chem; 18:263-265. 11. Evans M. and Rees A. (2002): Effects of HMG-CoA reductase inhibitors on skeletal muscle. Drug Safety; 25(9):649-663. 12. Fawcett JK. and Soctt JE. (1960): A rapid and precise method for the determination of urea. J Clin Path; 13: 156?159. 13. Gimenez LF., Solez K., and Walker W.G. (1987): Relation between renal calcium content and renal impairment in 246 human renal biopsies. Kidney International; 31: 93-99. 14. Targher G., Chonchol M., Zoppini G., Abaterusso C. and Bonora E. (2011): Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?. Journal of Hepatology, 54(5):1020-1029. 15. Grove TH. (1979): Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate-magnesium. Clin. Chem., 25 (4): 560-564. 16. Celebi G., Genc H., Gurel H., Sertoglu E., Kara M., Tapan S., Acikel C., Karslioglu Y., Ercin CN. and Dogru T. (2015): The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi Journal of Gastroenterology; 21(3): 139?145. 17. Harold V., Connerty MD., Anglis R. and Briggs BS. (1966): Determination of serum calcium by means of orthocresolphthalein complex one. Am J Clin Pathol; 45: 290-296. 18. Henninge AM., Staiger H., Wicke C., Machicao F., Fritsche A., H?ring HU. and Stefan N. (2008): Fetuin-A induce cytokine expression and suppresses adiponectin production. PLos One; 3. p.e1765. 19. Huddam B., Azak A., Ko?ak G., Bayraktar N. and Sezer S. (2013): The relationship between serum fetuin-A, cystatin-C levels, and microalbuminuria in patients with metabolic syndrome J Clin Lab Anal; 27(4):317-322. 20. Ismail NA., Ragab S., El Dayem SM., Elbaky AA., Salah N., Hamed M., Assal H. and Koura H. (2012): Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables Arch Med Sci. 9; 8(5):826-833. 21. Jaikumkao K., Pongchaidecha A., Thongnak L.O., Wanchai K., Arjinajarn P., Chatsudthipong V., Chattipakorn N. and Lungkaphin A. (2016): Amelioration of Renal Inflammation, Endoplasmic Reticulum Stress and Apoptosis Underlies the Protective Effect of Low Dosage of Atorvastatin in Gentamicin-Induced Nephrotoxicity. PloS One; 11(10):e0164528. 22. Jung UJ. and Choi MS. (2014): Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International Journal of Molecular Sciences; 15(4): 6184-6223. 23. Keiko E. (2016): Role of Oxidative Stress in Drug-Induced Kidney Injury. Int J Mol Sci. Nov; 17(11): 1826-1829. 24. Kostapanos MS, Florentin M. and Elisaf MS. (2013): Fenofibrate and the kidney: an overview. Eur J Clin Invest.; 43(5):522-531. 25. Kovesdy CP., Furth S. and Zoccali C.,(2017): World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. Journal of Endocrinology, Metabolism and Diabetes of South Africa; 22(1):5-11. 26. Kumar KV., Naidu MU., Shifow AA. and Ratnakar KS. (2000): Probucol protects against gentamicin-induced nephrotoxicity in rats. Indian Journal of Pharmacology; 32(2):108-113. 27. Li Y., Sun X. and Yu Y. (2013): Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats. BioMed Research International; 1-10. 28. McKeage K. and Keating GM. (2011): Fenofibrate: a review of its use in dyslipidaemia. Drugs; 71(14):1917-1946. 29. Matthews DR., Hosker JP., Rudenski AS., Naylor BA., Treacher DF. and Turner RC. (1985): Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28 (7): 412?419. 30. McGowan MW., Artiss JD., Standbergh DR., Strandbergh DR. and Zak B., (1983): Peroxidase-coupled method for colorimetric determination of serum triglycerides. Clin. Chem.; 29: 538-542. 31. Mardani S., Nasri H., Rafieian-Kopaei M. and Hajian S. (2013): Herbal medicine and diabetic kidney disease. Journal of Nephropharmacology, 2(1):1. 32. Stefan N., Artunc F., Heyne N., Machann J., Schleicher ED. and Haring HU. (2014): Obesity and renal disease: not all fat is created equal and not all obesity is harmful to the kidneys. Nephrology Dialysis Transplantation; 31(5): 726-730. 33. Novelli EL., Diniz YS., Galhardi CM., Ebaid GM., Rodrigues HG., Mani F., Fernandes AA., Cicogna AC. and Novelli Filho JL. (2007): Anthropometrical parameters and markers of obesity in rats. Lab Anim 41:111-119. 34. Ohkawa H., Ohishi W. and Yagi K. (1979): Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem; 95 (2): 351-358. 35. Oung HM, Lin KC, Wu TM, Chandrika NN, Hong CY(2015) ; Hygromycin B-induced cell death is partly mediated by reactive oxygen species in rice (Oryza sativa L.) Plant Mol Biol.; 89(6):577-588. 36. Ramsay TG., Stoll MJ., Blomberg LA. and Caperna TJ. (2017): Regulation of fetuin A gene expression in the neonatal pig liver. Animal; 13:1-7. 37. Buettner R., Scholmerich J. and Bollheimer LC. (2007): High fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity; 15(4):798-808. 38. Roos M., Eynatten MV., Heemann U., Rothenbacher D. and Breitling L, (2010): Serum Fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease. Am J Cardiol; 105(12):1666-1672. 39. Rosenson RS. (2009): Effect of Fenofibrate on Adiponectin and Inflammatory Biomarkers in Metabolic Syndrome Patients. Obesity; 17(3):407?616. 40. Sears B. and Perry M. (2015): The role of fatty acids in insulin resistance.Lipids Health Dis.;14: 121-124. 41. Tarantino N., Santoro F., De Gennaro L., Correale M., Guastafierro F., Gaglione A., Di Biase M. and Brunetti ND. (2017): Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vascular Health and Risk Management; 13:29-41. 42. Tietz NW. (1986): Determination of blood glucose, Text book of clinical chemistry. WB Saunders. Co. London, Philadelphia, 796. 43. Hunley TE., Ma LJ. and Kon V. (2010): Scope and mechanisms of obesity-related renal disease. Current opinion in nephrology and hypertension. 19(3):227-234. 44. Trepanowski JF., Mey J. and Varady KA. (2015): Fetuin-A: a novel link between obesity and related complications International Journal of Obesity; 39:734?741. 45. Tsao TS., Tomas E., Murrey HE., Hug C., Lee DH., Ruderman NB., Heuser JE. and Lodish HF.(2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem; 278(50): 810-817. 46. Tzanavari T, Giannogonas P, Karalis KP. (2010): TNF-alpha and obesity. Curr Dir Autoimmun;11:145-156. 47. Varga T., Czimmerer Z. and Nagy L. (2011): PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease; 1812(8):1007-1022. 48. Vaziri ND. and Moradi H. (2006): Mechanisms of dyslipidemia of chronic renal failure hemodialysis international ;10, Issue 1,1?7 49. Wagner R., Machann J., Guthoff M., Nawroth PP., Nadalin S., Saleem MA., Heyne N., Konigsrainer A., Fend F., Schick F. and Fritsche A.(2017): The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A. Scientific Reports, 7.Article number: 2261 50. Yan F., Wang Q., Xu C., Cao M., Zhou X., Wang T., Yu C., Jing, F., Chen W., Gao L. and Zhao J. (2014): Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. PloS One, 9(6):e99245. 51. Ye J. (2013): Mechanisms of insulin resistance in obesity. Front Med.; 7(1): 14?24.

How to Cite This Article

Rehab Ahmed Ahmed El-Shaer, Nahid Mohamed El-Fateh Tahoon, Mohamed Mohamed Madi and Salma Elwy Nassar. (2018); SERUM FETUIN- A LEVEL AND RENAL IMPAIRMENT INDUCED BY OBESITY IN COMPARISON WITH RENAL IMPAIRMENT INDUCED BY GENTAMICIN IN RATS., Int. J. of Adv. Res., 6 (02), 1792-1801, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/6619

Corresponding Author

rehab ahmed ahmed el-shaer
physiology
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.